Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease

Expert Opinion on Drug Safety

Volumn 14, Issue 4, 2015, Pages 533-541

  Matera, Maria Gabriella ^a   Cardaci, Vittorio ^b   Cazzola, Mario ^c   Rogliani, Paola ^c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Chronic obstructive pulmonary disease; Diabetes mellitus; Inhaled corticosteroids; Local side effects; Osteoporosis; Pneumonia; Systemic side effects.

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID;

CATARACT; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; COUGHING; DIABETES MELLITUS; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; FRACTURE; GLAUCOMA; HOARSENESS; HUMAN; HYPERGLYCEMIA; LARYNX DISORDER; LUNG TUBERCULOSIS; OROPHARYNX CANDIDIASIS; OSTEOPOROSIS; PERIORAL DERMATITIS; PHARYNX DISEASE; PNEUMONIA; REVIEW; RISK ASSESSMENT; SKIN MANIFESTATION; THRUSH; TREATMENT OUTCOME; DOSE RESPONSE; INHALATIONAL DRUG ADMINISTRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84924952712     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1001363     Document Type: Review

References (82)

1. National institute for health and clinical excellence.CG101 chronic obstructive pulmonary disease (update): full guideline 23 June 2010.Available from: http://www.nice.org [Last accessed 18 October 2014
2. Qaseem A, Wilt TJ, Weinberger SE, et al.Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society.Ann Intern Med 2011; 155: 179-91
3. Global initiative for chronic obstructive lung disease.global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.Revised 2014.Available from: http://www.goldcopd.org/.[Last accessed 18 October 2014
4. Miravitlles M, Soler-Cataluña JJ, Calle M, et al.Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD.Arch Bronconeumol 2012; 48: 247-57
5. Cazzola M, Rogliani P, Novelli L, Matera MG.Inhaled corticosteroids for chronic obstructive pulmonary disease.Expert Opin Pharmacother 2013; 14: 2489-99
6. Barnes PJ.Inhaled corticosteroids in COPD: a controversy.Respiration 2010; 80: 89-95
7. Price D, Yawn B, Brusselle G, Rossi A.Risk-To-benefit ratio of inhaled corticosteroids in patients with COPD.Prim Care Respir J 2013; 22: 92-100
8. Roland NJ, Bhalla RK, Earis J.The local side effects of inhaled corticosteroids: current understanding and review of the literature.Chest 2004; 126: 213-19
9. Irwin RS, Richardson ND.Side effects with inhaled corticosteroids: the physicians perception.Chest 2006; 130(1 Suppl): 41S-53S.
10. Barnes PJ.Inhaled corticosteroids.Pharmaceuticals 2010; 3: 514-40
11. Buhl R.Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma.Allergy 2006; 61: 518-26
12. Galván CA, Guarderas JC.Practical considerations for dysphonia caused by inhaled corticosteroids.Mayo Clin Proc 2012; 87: 901-4
13. Rachelefsky GS, Liao Y, Faruqi R.Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-Analysis.Ann Allergy Asthma Immunol 2007; 98: 225-38
14. Gallivan GJ, Gallivan KH, Gallivan HK.Inhaled corticosteroids: hazardous effects on voice-An update.J Voice 2007; 21: 101-11
15. Hira D, Koshiyama S, Komase Y, et al.Dry mouth as a novel indicator of hoarseness caused by inhalation therapy.J Asthma 2014; doi: 10.3109/02770903.2014.971965
16. Yang IA, Fong KM, Sim EH, et al.Inhaled corticosteroids for stable chronic obstructive pulmonary disease.Cochrane Database Syst Rev 2007; 2: CD002991
17. Sobieraj DM, White CM, Coleman CI.Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-Analysis.Clin Ther 2008; 30: 1416-25
18. Kurt E, Yildirim H, Kiraz N, et al.Oropharyngeal candidiasis with drypowdered fluticasone propionate: 500/.day versus 200 microg/day.Allergol Immunopathol (Madr) 2008; 36: 17-20
19. Ohbayashi H, Adachi M.Influence of dentures on residual inhaled corticosteroids in the mouths of elderly asthma patients.Respir Investig 2012; 50: 54-61
20. Kennedy WA, Laurier C, Gautrin D, et al.Occurrence and risk factors of oral candidiasis treated with oral antifungals in seniors using inhaled steroids.J Clin Epidemiol 2000; 53: 696-701
21. Vestbo J, Hurd SS, Agusti AC, et al.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.Am J Respir Crit Care Med 2013; 187: 347-65
22. Shim C, Williams MH.Cough and wheezing from beclomethasone aerosol.Chest 1987; 91: 207-9
23. Bryant DH, Pepys J.Bronchial reactions to aerosol inhalant vehicle.BMJ 1976; 1: 1319-20
24. Barnes NC.The properties of inhaled corticosteroids: similarities and differences.Prim Care Respir J 2007; 16: 149-54
25. Kardos P, Wencker M, Glaab T, Vogelmeier C.Impact of salmeterol/.fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.Am J Respir Crit Care Med 2007; 175: 144-9
26. Calverley P, Anderson J, Celli B, et al.Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.N Engl J Med 2007; 356: 775-89
27. Crim C, Calverley PM, Anderson JA, et al.Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.Eur Respir J 2009; 34: 641-7
28. Anzueto A, Ferguson GT, Feldman G, et al.Effect of fluticasone propionate/.salmeterol (250/50) on COPD exacerbations and impact on patient outcomes.COPD 2009; 6: 320-9
29. Ferguson GT, Anzueto A, Fei R, et al.Effect of fluticasone propionate/.salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.Respir Med 2008; 102: 1099-108
30. Wedzicha JA, Calverley PM, Seemungal TA, et al.The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.Am J Respir Crit Care Med 2008; 177: 19-26
31. Dransfield MT, Bourbeau J, Jones PW, et al.Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.Lancet Respir Med 2013; 1: 210-23
32. Suissa S, Patenaude V, Lapi F, Ernst P.Inhaled corticosteroids in COPD and the risk of serious pneumonia.Thorax 2013; 68: 1029-36
33. Janson C, Larsson K, Lisspers KH, et al.Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting b2 agonist: observational matched cohort study (PATHOS).BMJ 2013; 346: f3306
34. Kew KM, Seniukovich A.Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.Cochrane Database Syst Rev 2014; 3: CD010115
35. DiSantostefano RL, Sampson T, Le HV, et al.Risk of pneumonia with inhaled corticosteroid versus long-Acting bronchodilator regimens in chronic obstructive pulmonary disease: a newuser cohort study.PLoS One 2014; 9: e97149
36. Sibila O, Laserna E, Mortensen EM, et al.Effects of inhaled corticosteroids on pneumonia severity and antimicrobial resistance.Respir Care 2013; 58: 1489-94
37. Finney L, Berry M, Singanayagam A, et al.Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease.Lancet Respir Med 2014; doi: 10.1016/S2213-2600(14) 70169-9
38. Calverley PMA.Inhaled corticosteroids as a cause of CAP.Eur Respir Mon 2014; 63: 234-42
39. Singanayagam A, Chalmers JD.Budesonide and risk of pneumonia.Lancet 2009; 374: 2050
40. Malo de Molina R, Mortensen EM, Restrepo MI, et al.Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalized with pneumonia.Eur Respir J 2010; 36: 751-7
41. Loke YK, Kwok CS, Wong JM, et al.Chronic obstructive pulmonary disease and mortality from pneumonia: meta-Analysis.Int J Clin Pract 2013; 67: 477-87
42. Ni S, Fu Z, Zhao J, Liu H.Inhaled corticosteroids (ICS) and risk of mycobacterium in patients with chronic respiratory diseases: a meta-Analysis.J Thorac Dis 2014; 6: 971-8
43. Chung WS, Chen YF, Hsu JC, et al.Inhaled corticosteroids and the increased risk of pulmonary tuberculosis: a population-based case-control study.Int J Clin Pract 2014; 68: 1193-9
44. Brassard P, Suissa S, Kezouh A, Ernst P.Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases.Am J Respir Crit Care Med 2011; 183: 675-8
45. Kim JH, Park JS, Kim KH, et al.Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD.Chest 2013; 143: 1018-24
46. Dong YH, Chang CH, Lin Wu FL, et al.Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: a systematic review and meta-Analysis of randomized controlled trials A systematic review and metaanalysis of randomized controlled trials.Chest 2014; 145: 1286-97
47. Ferguson GT, Calverley PM, Anderson JA, et al.Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study.Chest 2009; 136: 1456-65
48. Yang IA, Clarke MS, Sim EH, Fong KM.Inhaled corticosteroids for stable chronic obstructive pulmonary disease.Cochrane Database Syst Rev 2012; 7: CD002991
49. Scanlon PD, Connett JE, Wise RA, et al.Loss of bone density with inhaled triamcinolone in Lung Health Study II.Am J Respir Crit Care Med 2004; 170: 1302-9
50. Loke YK, Cavallazzi R, Singh S.Risk of fractures with inhaled corticosteroids in COPD: systematic review and metaanalysis of randomised controlled trials and observational studies.Thorax 2011; 66: 699-708
51. Kelly HW, Nelson HS.Potential adverse effects of inhaled corticosteroids.J Allergy Clin Immunol 2003; 112: 469-78
52. Lehouck A, Boonen S, Decramer M, Janssens W.COPD, bone metabolism, and osteoporosis.Chest 2011; 139: 648-57
53. Suissa S, Kezouh A, Ernst P.Inhaled corticosteroids and the risks of diabetes onset and progression.Am J Med 2010; 123: 1001-6
54. Rogliani P, Calzetta L, Segreti A, et al.Diabetes mellitus among outpatients with COPD attending a university hospital.Acta Diabetol 2014; doi: 10.1007/s00592-014-0584-0
55. Caughey GE, Preiss AK, Vitry AI, et al.Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications.Diabetes Care 2013; 36: 3009-14
56. Barnes PJ.Chronic obstructive pulmonary disease: effects beyond the lungs.PLoS Med 2010; 7: e1000220
57. Slatore CG, Bryson CL, Au DH.The association of inhaled corticosteroid use with serum glucose concentration in a large cohort.Am J Med 2009; 122: 472-8
58. Baker EH, Clark N, Brennan AL, et al.Hyperglycemia and cystic fibrosis alter respiratory fluid glucose concentrations estimated by breath condensate analysis.J Appl Physiol 2007; 102: 1969-75
59. Cazzola M, Calzetta L, Rogliani P, et al.High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway.Am J Respir Cell Mol Biol 201247: 509-16
60. Lung Health Study Research Group.Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.N Engl J Med 2000; 343: 1902-9
61. OByrne PM, Rennard S, Gerstein H, et al.Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids.Respir Med 2012; 106: 1487-93
62. Miller DP, Watkins SE, Sampson T, Davis KJ.Long-Term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database.Int J Chron Obstruct Pulmon Dis 2011; 6: 467-76
63. Weatherall M, Clay J, James K, et al.Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-Analysis.Respirology 2009; 14: 983-90
64. Uboweja A, Malhotra S, Pandhi P.Effect of inhaled corticosteroids on risk of development of cataract: a meta-Analysis development of cataract: a meta-Analysis.Fundam Clin Pharmacol 2006; 20: 305-30
65. Wang JJ, Rochtchina E, Tan AG, et al.Use of inhaled and oral corticosteroids and the long-Term risk of cataract.Ophthalmology 2009; 116: 652-7
66. Basoglu OK, Emre S, Bacakoglu F, Ates H.Glaucoma associated with metered-dose bronchodilator therapy.Respir Med 2001; 95: 844-5
67. Zervas E, Samitas K, Gaga M, et al.Inhaled corticosteroids in COPD: pros and cons.Curr Drug Targets 2013; 14: 192-224
68. Geller DE.Clinical side effects during aerosol therapy: cutaneous and ocular effects.J Aerosol Med 2007; 20(Suppl 1): S100-8
69. Tashkin DP, Murray HE, Skeans M, Murray RP.Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II.Chest 2004; 126: 1123-33
70. Capewell S, Reynolds S, Shuttleworth D, et al.Purpura and dermal thinning associated with high dose inhaled corticosteroids.BMJ 1990; 300: 1548-51
71. Pauwels RA, Lofdahl CG, Laitinen LA, et al.Long-Term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking.European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.N Engl J Med 1999; 340: 1948-53
72. Cazzola M, Bettoncelli G, Sessa E, et al.Prevalence of comorbidities in patients with chronic obstructive pulmonary disease.Respiration 2010; 80: 112-19
73. Ionescu AA, Schoon E.Osteoporosis in chronic obstructive pulmonary disease.Eur Respir J 2003; 46(suppl): 64s-75s
74. Dimai HP, Domej W, Leb G, Lau K.Bone loss in patients with untreated chronic obstructive pulmonary disease is mediated by an increase in bone resorption associated with hypercapnia.J Bone Miner Res 2001; 16: 2132-41
75. Mineo TC, Ambrogi V, Mineo D, et al.Bone mineral density improvement after lung volume reduction surgery for severe emphysema.Chest 2005; 127: 1960-6
76. Heianza Y, Arase Y, Tsuji H, et al.Low lung function and risk of type 2 diabetes in Japanese men: the Toranomon Hospital Health Management Center Study 9 (TOPICS 9).Mayo Clin Proc 2012; 87: 853-61
77. Wang X, Bao W, Liu J, et al.Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-Analysis.Diabetes Care 2013; 36: 166-75
78. Song Y, Klevak A, Manson JE, et al.Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Womens Health Study.Diabetes Res Clin Pract 2010; 90: 365-71
79. Müllerova H, Chigbo C, Hagan GW, et al.The natural history of communityacquired pneumonia in COPD patients: a population database analysis.Respir Med 2012; 106: 1124-33
80. Metlay JP, Kapoor WN, Fine MJ.Does this patient have community-Acquired pneumonia?.Diagnosing pneumonia by history and physical examination.JAMA 1997; 278: 1440-5
81. Festic E, Bansal V, Gajic O, Lee AS.Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study.Mayo Clin Proc 2014; 89: 154-62
82. Calverley PMA, Stockley RA, Seemungal TAR, et al.Reported pneumonia in patients with COPD: findings from the INSPIRE studyChest 2011; 139: 505-12